Floatz logo

Dasatinib

Chronic Myelogenous Leukemia

OHSU Knight Cancer InstituteSmall moleculePhase 2/3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
81/ 100

Competitive context

86 Active assets in the Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB
METHOTREXATE
M.D. Anderson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Dasatinib is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →